Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...

Scynexis has resumed dosing of its Brexafemme (ibrexafungerp) drug in a Phase III trial after a 19-month clinical hold by the ...

The US FDA has granted regenerative medicine advanced therapy (RMAT) designation to AbelZeta Pharma’s C-CAR168.

In the race to decarbonize the global economy, advanced materials are no longer a luxury – they’re a necessity.

PL logistics need to invest in new technology and upskilling programs to scale their cell and gene therapy services.

GlycoEra has closed an oversubscribed Series B financing round, raising $130m, to support its lead IgG4-targeted protein ...

Biogen and City Therapeutics are to partner for the development of new RNA interference (RNAi) therapies. Leveraging ...